Welcome to our dedicated page for ASTERA LABS SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
Astera Labs (ALAB) Form 4 reports two consecutive insider sales by CEO & Director Jitendra Mohan on 17-18 Jul 2025 pursuant to a Rule 10b5-1 plan adopted 2 Dec 2024.
- 17 Jul 2025: 80,503 common shares sold through six estate-planning trusts at a weighted-average price of $94.37.
- 18 Jul 2025: 45,755 common shares sold through the same trusts at a weighted-average price of $100.25.
Total disposition: 126,258 shares (~1 % of reported holdings). Post-sale beneficial ownership remains substantial at roughly 9.8 million shares, including 2.26 million held directly and 7.54 million held indirectly across multiple trusts.
No derivative activity was disclosed. Because the sales were automatic and represent a small fraction of total ownership, they appear to be routine liquidity events; however, investors may monitor future filings for additional insider trends.
Astera Labs, Inc. (ALAB) – Form 4 insider transaction filed 07/11/2025
President, COO and Director Sanjay Gajendra reported the sale of 165,000 ALAB common shares on 07/09/2025 through three estate-planning trusts ("Trust 1", "Trust 2", "Trust 3") operating under a Rule 10b5-1 trading plan adopted on 11/30/2024.
- Shares sold & weighted-average prices
- Trust 1: 86,685 sh @ $98.5214 and 38,315 sh @ $99.2093
- Trust 2: 20,000 sh @ $98.2078
- Trust 3: 20,000 sh @ $98.2180
- Total shares sold: 165,000
- Approximate gross proceeds: ≈ $16.3 million (calculated from disclosed share counts and prices)
- Remaining holdings (indirect only):
- Trust 1: 5,805,545 shares
- Trust 2: 695,000 shares
- Trust 3: 695,000 shares
- Direct holding disclosed separately: 2,262,318 shares
The filing notes that Mr. Gajendra disclaims beneficial ownership except to the extent of any pecuniary interest and that the sales occurred automatically under the pre-set 10b5-1 plan, potentially mitigating concerns about timing or intent.
No derivative security transactions were reported. The sale reduces—but does not materially alter—the insider’s significant economic exposure, leaving a combined direct and indirect stake exceeding 9.4 million shares.
Astera Labs, Inc. (ALAB) has filed a Form 4 disclosing that Chief Executive Officer and Director Jitendra Mohan sold company stock on 9 and 10 July 2025 pursuant to a Rule 10b5-1 trading plan adopted 2 December 2024. In total, 18,264 common shares were sold through several estate-planning trusts at weighted-average prices of $100.0092 (6,982 shares on 7/09) and $102.4607 (11,282 shares on 7/10). Footnotes note price ranges of $100.00–$100.08 and $102.04–$103.14, respectively.
Following the transactions the trusts still hold a combined ≈7.6 million shares, while a separate direct holding of 2,262,318 shares is also reported, indicating that less than 1 % of Mohan’s beneficial ownership was divested. No derivative securities were involved, and the sales were executed automatically, limiting their informational content regarding future company prospects.